BACKGROUND: MAGI is an acronym that identifies the "male accessory gland inflammations/infections", a potential cause of male infertility. Type 2 diabetes mellitus (DM2) prevalence is going to increase among men of reproductive age. Due to the high prevalence of these two conditions, we could suppose that they might appear together in the same patient. AIM: To evaluate MAGI prevalence in patients with DM2 in fertile age. SUBJECTS AND METHODS: A cross-sectional study carried out on patients with DM2 of fertile age. All patients underwent andrological evaluation for the identification of conventional MAGI diagnostic criteria. RESULTS: DM2 patients showed a frequency of MAGI about 43%, significantly lower (p<0.05) than in infertile patients of the same age without diabetes, which showed a MAGI overall frequency of 61%. Among examined diabetic patients the prevalence of MAGI did not significantly differ between patients attending for diabetes care problems (glycemic control) and patients with andrological disorders. Finally, no significant difference in seminal inflammatory signs frequency was detected between patients with DM2 and infertile patients without diabetes. Finally, the correlation analysis showed a significant direct correlation between duration of diabetes and glycemic control with the prevalence of MAGI. CONCLUSION: MAGI prevalence in DM2 is lower than the one detected in age-matched infertile non-diabetic patients, however, as in infertile patients, there is a high frequency of seminal inflammatory signs. Moreover, the observed prevalence among diabetic patients with diabetes care problems and diabetic patients with andrological problems is not statistically different.
BACKGROUND: MAGI is an acronym that identifies the "male accessory gland inflammations/infections", a potential cause of male infertility. Type 2 diabetes mellitus (DM2) prevalence is going to increase among men of reproductive age. Due to the high prevalence of these two conditions, we could suppose that they might appear together in the same patient. AIM: To evaluate MAGI prevalence in patients with DM2 in fertile age. SUBJECTS AND METHODS: A cross-sectional study carried out on patients with DM2 of fertile age. All patients underwent andrological evaluation for the identification of conventional MAGI diagnostic criteria. RESULTS:DM2patients showed a frequency of MAGI about 43%, significantly lower (p<0.05) than in infertilepatients of the same age without diabetes, which showed a MAGI overall frequency of 61%. Among examined diabeticpatients the prevalence of MAGI did not significantly differ between patients attending for diabetes care problems (glycemic control) and patients with andrological disorders. Finally, no significant difference in seminal inflammatory signs frequency was detected between patients with DM2 and infertilepatients without diabetes. Finally, the correlation analysis showed a significant direct correlation between duration of diabetes and glycemic control with the prevalence of MAGI. CONCLUSION: MAGI prevalence in DM2 is lower than the one detected in age-matched infertile non-diabeticpatients, however, as in infertilepatients, there is a high frequency of seminal inflammatory signs. Moreover, the observed prevalence among diabeticpatients with diabetes care problems and diabeticpatients with andrological problems is not statistically different.
Authors: Allison A Hedley; Cynthia L Ogden; Clifford L Johnson; Margaret D Carroll; Lester R Curtin; Katherine M Flegal Journal: JAMA Date: 2004-06-16 Impact factor: 56.272
Authors: Dana Dabelea; Ronny A Bell; Ralph B D'Agostino; Giuseppina Imperatore; Judith M Johansen; Barbara Linder; Lenna L Liu; Beth Loots; Santica Marcovina; Elizabeth J Mayer-Davis; David J Pettitt; Beth Waitzfelder Journal: JAMA Date: 2007-06-27 Impact factor: 56.272
Authors: Giovanni Corona; Andrea M Isidori; Antonio Aversa; Marco Bonomi; Alberto Ferlin; Carlo Foresta; Sandro La Vignera; Mario Maggi; Rosario Pivonello; Linda Vignozzi; Francesco Lombardo Journal: Rev Endocr Metab Disord Date: 2020-03 Impact factor: 6.514
Authors: R A Condorelli; A E Calogero; E Vicari; V Favilla; S Cimino; G I Russo; G Morgia; S La Vignera Journal: Int J Endocrinol Date: 2014-09-08 Impact factor: 3.257
Authors: Rosita A Condorelli; Sandro La Vignera; Laura M Mongioì; Angela Alamo; Aldo E Calogero Journal: Front Endocrinol (Lausanne) Date: 2018-05-25 Impact factor: 5.555
Authors: Sandro La Vignera; Rosita A Condorelli; Rossella Cannarella; Filippo Giacone; Laura M Mongioi'; Laura Cimino; Giuseppe Defeudis; Rossella Mazzilli; Aldo E Calogero Journal: Int J Immunopathol Pharmacol Date: 2019 Jan-Dec Impact factor: 3.219
Authors: Sandro La Vignera; Andrea Crafa; Rosita A Condorelli; Federica Barbagallo; Laura M Mongioì; Rossella Cannarella; Michele Compagnone; Antonio Aversa; Aldo E Calogero Journal: Andrology Date: 2021-05-06 Impact factor: 3.842
Authors: Sandro La Vignera; Andrea Crafa; Rosita A Condorelli; Federica Barbagallo; Laura M Mongioì; Rossella Cannarella; Michele Compagnone; Antonio Aversa; Aldo E Calogero Journal: Andrology Date: 2021-05-04 Impact factor: 3.842